Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoid Clear all
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo
Biological
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis

NCT01013311
View directory record Official record
Conditions
Sarcoidosis of the Heart, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jul 21, 2026, 6:11 PM EDT
Not yet recruiting No phase listed Observational

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

NCT07613216
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions
Not listed
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Suspected Association Between Sarcoidosis and Development of Diabetes Mellitus

NCT03805633
View directory record Official record
Conditions
Sarcoidosis, Diabetes Mellitus
Interventions
Venous blood sample, Ultrasound of pancreas
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Evaluation of MyoStrain™ in Clinical Practice

NCT03825224
View directory record Official record
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Phase 4 Interventional Results available

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092
View directory record Official record
Conditions
Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Genomic Research in Sarcoidosis

NCT01831739
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 4 Interventional Results available

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

NCT03549598
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT02546388
View directory record Official record
Conditions
Sarcoidosis
Interventions
Indium-111 Pentreotide, Gallium-68 DOTATATE
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Results available

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

NCT03103490
View directory record Official record
Conditions
Cardiac Sarcoidosis, Myocardial Inflammation
Interventions
18F-FSPG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

NCT02656381
View directory record Official record
Conditions
Uveitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
8 Years to 100 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

NCT05351554
View directory record Official record
Conditions
Sarcoidosis, Cardiac
Interventions
Namilumab
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin to Treat Pulmonary Sarcoidosis

NCT00279708
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Atorvastatin, Placebo Oral Tablet
Drug · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mayo AVC Registry and Biobank

NCT03049254
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Sudden Cardiac Arrest, Sudden Cardiac Death, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Familial Dilated Cardiomyopathy, Cardiovascular Abnormalities, Sarcoidosis, Cardiac Arrhythmia, Cardiac Sarcoidosis, Myocarditis, Inflammatory Cardiomyopathy, Ventricular Tachycardia, Right Ventricular Outflow Tract Ventricular Tachycardia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

NCT02036970
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions
Bardoxolone methyl, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational

Study of Eye Tissue for Sarcoidosis

NCT00001278
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:11 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT06169397
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
XTMAB-16
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

NCT04064242
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
CMK389, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Gainesville, Florida • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 21, 2026, 6:11 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jul 21, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 21, 2026, 6:11 PM EDT
Withdrawn Phase 4 Interventional

ACTHAR Therapy for Central Nervous System Sarcoidosis

NCT02920710
View directory record Official record
Conditions
Sarcoidosis
Interventions
Repository Corticotropin Injection
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jul 21, 2026, 6:11 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 21, 2026, 6:11 PM EDT